ARQT - FDA Approval for the Treatment of Seborrheic Dermatitis has this Listing Popping

2023-12-18 07:29:52 ET

DENVER, Colo., Dec 18, 2023 ( www.247marketnews.com )- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported, after Friday’s market close, that the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older, as nearly 80% of individuals achieved the primary efficacy endpoint of IGA Success and just over 50% of individuals reached complete clearance at Week 8 in the STRATUM trial. ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Arcutis Biotherapeutics is trading at $3.06, up $0.62 (+25.41%), on 3.1M shares traded.

Its 52-week …

The post FDA Approval for the Treatment of Seborrheic Dermatitis has this Listing Popping appeared first on 24/7 Market News .

For further details see: